Immune thrombocytopenia (ITP) is a rare autoimmune disorder presenting with isolated thrombocytopenia. Splenectomy is still one of the treatment alternatives for these patients. Here we aim to analyze long term follow-up data of splenectomy in immune thrombocytopenia. This retrospectively designed study was conducted in a tertiary health clinic. Patients with ITP who were splenectomized between 1990 and 2015 were included. Response to treatment was interpreted as ‘complete response', ‘response' or ‘no response'. The incidence of response loss was evaluated. Perioperative and long term complications and overall survival rates were determined. Out of 51 patients, who underwent splenectomy after 12 months of diagnosis, 47 achieved a response (92.2%). Of 47 patients who had a platelet count at least 30.000/µL, 41 (87.2%) had CR. Incidence of loss of response was 10.5% (95% confidence interval (CI): 4%-26.1%) at 30 months. Two patients died, and overall survival rate was 97.4% (95% CI: 82.8%-99.6%) at 30 months of follow up. Considering the complications: two patients had venous thromboembolism, 11 had minor bleeding episodes and 15 suffered from perioperative infections. Our study suggests that splenectomy promises a high level of response with acceptable complication rates. Although less preferred recently, splenectomy should still be taken into consideration when remission is not achieved especially after 12 months of disease.

免疫性血小板减少症（ITP）是一种罕见的自身免疫性疾病，表现为孤立性血小板减少症。脾切除术仍然是这些患者的治疗选择之一。在这里，我们的目的是分析免疫性血小板减少症脾切除术的长期随访数据。这项回顾性设计的研究是在一家三级医疗诊所进行的。纳入 1990 年至 2015 年间接受脾切除的 ITP 患者。对治疗的反应被解释为“完全反应”、“反应”或“无反应”。评估反应损失的发生率。确定围手术期和长期并发症以及总生存率。在诊断 12 个月后接受脾切除术的 51 名患者中，47 名患者获得缓解 (92.2%)。在 47 名血小板计数至少为 30.000/μL 的患者中，41 名 (87.2%) 获得 CR。30 个月时失去反应的发生率为 10.5%（95% 置信区间 (CI)：4%-26.1%）。两名患者死亡，随访 30 个月时总生存率为 97.4%（95% CI：82.8%-99.6%）。考虑到并发症：2名患者出现静脉血栓栓塞，11名患者出现轻微出血，15名患者出现围手术期感染。我们的研究表明，脾切除术可带来高水平的缓解，并且并发症发生率可接受。虽然最近不太推荐，但当未达到缓解时，尤其是在疾病 12 个月后，仍应考虑脾切除术。2 名患者出现静脉血栓栓塞，11 名患者出现轻微出血，15 名患者出现围手术期感染。我们的研究表明，脾切除术可带来高水平的缓解，并且并发症发生率可接受。虽然最近不太推荐，但当未达到缓解时，尤其是在疾病 12 个月后，仍应考虑脾切除术。2 名患者出现静脉血栓栓塞，11 名患者出现轻微出血，15 名患者出现围手术期感染。我们的研究表明，脾切除术可带来高水平的缓解，并且并发症发生率可接受。虽然最近不太推荐，但当未达到缓解时，尤其是在疾病 12 个月后，仍应考虑脾切除术。